Column Group LLC — Q1 2026 13F-HR

← Column Group LLC

Q1 2026 · 13F-HR

Column Group LLCholdings as filed

Filed 2026-05-18 · accession 0001193125-26-227853

$100.7M

Reported value

Positions

2026-03-31

Period end

View analyzed profile →PRO

The Brief · Column Group LLC · Q1 2026

AI · grounded in 13F

Column Group LLC closed its position in Tenaya Therapeutics, Inc. TNYA, reducing its holdings by $6.69M. The fund also exited its position in RAPT Therapeutics Inc, resulting in a $5.29M decrease. Conversely, the fund accumulated shares of Surrozen, Inc., increasing its position by 3.54%.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
86889P109	—	Surrozen, Inc.	$55.8M	55.4%	1,916,950	Common	SOLE
68622P109	ORIC	ORIC Pharmaceuticals Inc.	$44.9M	44.5%	3,540,777	Common	SOLE
76155X100	RVMD	Revolution Medicines Inc	$4,474	0.00%	46	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.